Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBT (2020 - 2025)

Historic EBT for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to -$7.8 million.

  • Cytek Biosciences' EBT fell 504840.76% to -$7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.5 million, marking a year-over-year decrease of 3002.27%. This contributed to the annual value of -$5.7 million for FY2024, which is 6371.51% up from last year.
  • Cytek Biosciences' EBT amounted to -$7.8 million in Q3 2025, which was down 504840.76% from -$6.8 million recorded in Q2 2025.
  • Cytek Biosciences' 5-year EBT high stood at $10.3 million for Q4 2024, and its period low was -$11.3 million during Q1 2025.
  • Its 5-year average for EBT is -$2.1 million, with a median of -$1.4 million in 2022.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 160156.25% in 2021, then tumbled by 504840.76% in 2025.
  • Quarter analysis of 5 years shows Cytek Biosciences' EBT stood at $444000.0 in 2021, then soared by 826.58% to $4.1 million in 2022, then dropped by 0.07% to $4.1 million in 2023, then skyrocketed by 151.11% to $10.3 million in 2024, then plummeted by 175.26% to -$7.8 million in 2025.
  • Its EBT stands at -$7.8 million for Q3 2025, versus -$6.8 million for Q2 2025 and -$11.3 million for Q1 2025.